New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 26, 2012
07:17 EDTAEGRAegerion label for Juxtapid looks favorable, says JPMorgan
JPMorgan views the label for Aegerion's Juxtapid as favorable and reiterates an Overweight rating on the stock after the FDA approved the drug. The firm upped its price target for shares to $30 from $28.
News For AEGR From The Last 14 Days
Check below for free stories on AEGR the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 31, 2014
11:33 EDTAEGROptions with decreasing implied volatility
Subscribe for More Information
July 30, 2014
09:04 EDTAEGROn The Fly: Pre-market Movers
Subscribe for More Information
08:11 EDTAEGRAegerion appoints Craig Fraser as COO
Subscribe for More Information
06:29 EDTAEGRAegerion shares due for 'significant positive bounce,' says Leerink
Subscribe for More Information
July 29, 2014
18:35 EDTAEGROn The Fly: After Hours Movers
Subscribe for More Information
16:49 EDTAEGRAegerion sees 2014 JUXTAPID sales at low end of range
Subscribe for More Information
16:48 EDTAEGRAegerion reports Q2 EPS (6c), consensus (41c)
Reports Q2 revenue $36M, consensus $35.4M.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use